Aspirin reduces prostate cancer risk by 30 percent

London, Aug 13, 2010 :

A regular dose of aspirin can reduce prostate cancer risk by 30 percent, a study has found.

Regular intake of 75mg tablet has been found to have strong effects against the disease. It blocks the effect of enzymes that can cause inflammation, which is believed to be a key factor in the development of prostate cancer.

Scientists at the Fred Hutchinson Cancer Research Centre in Seattle studied two groups of men - 1,001 prostate cancer sufferers and 942 cancer-free volunteers of a similar age.

When the experts looked at how often men in both groups took aspirin, they found higher usage among the cancer-free volunteers, reports dailymail.co.uk.

The findings revealed that men who had used aspirin at any point in the previous 12 months were 21 percent less likely to develop a tumour.

Those who took aspirin frequently for five years or more had 24 percent decreased risk. In this group, the chances of developing prostate cancer dropped by 29 percent.

The research team said that aspirin appears to dampen the effects of two particular enzymes that stimulate inflammation in the prostate PTGS1 and PTGS2.